ATTR clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Patients With Transthyretin (ATTR) Amyloidosis
Sorry, not currently recruiting here
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
San Francisco, California and other locations
Last updated: